Afuresertib

Cat. No.: 0225LY-1091

Appearance: Solid

Purity: ≥99%

Identity: Confirmed by NMR, and LC-MS.

Size:

INQUIRY Datasheet MSDS

Add to basket

Product Overview

Description: Afuresertib is an orally active inhibitor of Akt (protein kinase B) currently being studied for its antineoplastic potential.

Synonym: GSK2110183C; GSK2110183; 1047644-62-1; GSK-2110183; GSK2110183C; N-[(2S)-1-amino-3-(3-fluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-2-methylpyrazol-3-yl)thiophene-2-carboxamide; 2-Thiophenecarboxamide, N-((1S)-2-amino-1-((3-fluorophenyl)methyl)ethyl)-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-; N-((1S)-1-(aminomethyl)-2-(3-fluorophenyl)ethyl)-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)thiophene-2-carboxamide; N-((S)-1-amino-3-(3-fluorophenyl)propan-2-yl)-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)thiophene-2-carboxamide; N-[(2S)-1-amino-3-(3-fluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)thiophene-2-carboxamide; afuresertibum

CAS No.: 1047644-62-1

Compound CID: 46843057

Formula: C₁₈H₁₇Cl₂FN₄OS

Formula Weight: 427.32

Specification

Targets&IC50: Akt3: 2.6 nM(Ki); Akt1: 0.08 nM(Ki); Akt2: 2 nM(Ki)

Relative Density: 1.49 g/cm³

Stability: 3 years in powder form.

Storage: Storage at -20°C.

Applications: Afuresertib can be used in drug screening assays to evaluate the therapeutic potential of targeting the AKT pathway in resistant cancers.